Literature DB >> 25248353

Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.

Michael G Doran, Daniel E Spratt, John Wongvipat, David Ulmert, Brett S Carver, Charles L Sawyers, Michael J Evans.   

Abstract

The receptor tyrosine kinase inhibitor cabozantinib (XL184, BMS-907351 Cometriq) has displayed impressive clinical activity against several indications, culminating in its recent approval for medullary thyroid cancer. Among malignancies with tropism for the bone (prostate, breast), one striking feature of early clinical reports about this drug has been the rapid and complete resolution of bone scans, a phenomenon almost never observed even among therapies already shown to confer survival benefit. In castration-resistant prostate cancer, not all conventional response indicators change as dramatically posttreatment, raising the possibility that cabozantinib may impair the ability of bone-seeking radionuclides to integrate within the remodeling bone. To test this hypothesis, we surgically induced bone remodeling via physical insult in non-tumor-bearing mice and performed 18F-sodium fluoride (18F-NaF) positron emission tomographic (PET) and technetium 99m-methylene diphosphonate (99mTc-MDP) single-photon emission computed tomographic (SPECT) scans pre- and posttreatment with cabozantinib and related inhibitors. A consistent reduction in the accumulation of either radiotracer at the site of bone remodeling was observed in animals treated with cabozantinib. Given that cabozantinib is known to inhibit several receptor tyrosine kinases, we drugged animals with various permutations of more selective inhibitors to attempt to refine the molecular basis of bone scan resolution. Neither the vascular endothelial growth factor receptor (VEGFR) inhibitor axitinib, the MET inhibitor crizotinib, nor the combination was capable of inhibiting 18F-NaF accumulation at known bioactive doses. In summary, although the mechanism by which cabozantinib suppresses radionuclide incorporation into foci undergoing bone remodeling remains unknown, that this phenomenon occurs in tumor-naïve models indicates that caution should be exercised in interpreting the clinical significance of this event.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25248353      PMCID: PMC4545649          DOI: 10.2310/7290.2014.00026

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  20 in total

Review 1.  Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).

Authors:  D W Bowles; E R Kessler; A Jimeno
Journal:  Drugs Today (Barc)       Date:  2011-11       Impact factor: 2.245

2.  Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

Authors:  Sergei L Timofeevski; Michele A McTigue; Kevin Ryan; Jean Cui; Helen Y Zou; Jeff X Zhu; Fannie Chau; Gordon Alton; Shannon Karlicek; James G Christensen; Brion W Murray
Journal:  Biochemistry       Date:  2009-06-16       Impact factor: 3.162

3.  Computer-aided quantitative bone scan assessment of prostate cancer treatment response.

Authors:  Matthew S Brown; Gregory H Chu; Hyun J Kim; Martin Allen-Auerbach; Cheryce Poon; Juliette Bridges; Adria Vidovic; Bharath Ramakrishna; Judy Ho; Michael J Morris; Steven M Larson; Howard I Scher; Jonathan G Goldin
Journal:  Nucl Med Commun       Date:  2012-04       Impact factor: 1.690

Review 4.  The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials.

Authors:  Andreas Varkaris; Paul G Corn; Sanchaika Gaur; Farshid Dayyani; Christopher J Logothetis; Gary E Gallick
Journal:  Expert Opin Investig Drugs       Date:  2011-10-28       Impact factor: 6.206

5.  Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Authors:  F Michael Yakes; Jason Chen; Jenny Tan; Kyoko Yamaguchi; Yongchang Shi; Peiwen Yu; Fawn Qian; Felix Chu; Frauke Bentzien; Belinda Cancilla; Jessica Orf; Andrew You; A Douglas Laird; Stefan Engst; Lillian Lee; Justin Lesch; Yu-Chien Chou; Alison H Joly
Journal:  Mol Cancer Ther       Date:  2011-09-16       Impact factor: 6.261

Review 6.  Novel therapies for metastatic castrate-resistant prostate cancer.

Authors:  Farshid Dayyani; Gary E Gallick; Christopher J Logothetis; Paul G Corn
Journal:  J Natl Cancer Inst       Date:  2011-09-13       Impact factor: 13.506

7.  Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

Authors:  David C Smith; Matthew R Smith; Christopher Sweeney; Aymen A Elfiky; Christopher Logothetis; Paul G Corn; Nicholas J Vogelzang; Eric J Small; Andrea L Harzstark; Michael S Gordon; Ulka N Vaishampayan; Naomi B Haas; Alexander I Spira; Primo N Lara; Chia-Chi Lin; Sandy Srinivas; Avishay Sella; Patrick Schöffski; Christian Scheffold; Aaron L Weitzman; Maha Hussain
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

Review 8.  Dynamic bone imaging with 99mTc-labeled diphosphonates and 18F-NaF: mechanisms and applications.

Authors:  Ka Kit Wong; Morand Piert
Journal:  J Nucl Med       Date:  2013-03-12       Impact factor: 10.057

9.  Phase II study of sunitinib in men with advanced prostate cancer.

Authors:  M Dror Michaelson; M M Regan; W K Oh; D S Kaufman; K Olivier; S Z Michaelson; B Spicer; C Gurski; P W Kantoff; M R Smith
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

10.  Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.

Authors:  Philip J Saylor; Umar Mahmood; Anchisa Kunawudhi; Matthew R Smith; Edwin L Palmer; M Dror Michaelson
Journal:  J Nucl Med       Date:  2012-09-14       Impact factor: 10.057

View more
  3 in total

Review 1.  Contemporary approaches for imaging skeletal metastasis.

Authors:  David Ulmert; Lilja Solnes; Daniel Lj Thorek
Journal:  Bone Res       Date:  2015-07-14       Impact factor: 13.567

2.  Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.

Authors:  Raya Leibowitz-Amit; Melania Pintilie; Leila Khoja; Arun A Azad; Raanan Berger; A Douglas Laird; Dana T Aftab; Kim N Chi; Anthony M Joshua
Journal:  J Transl Med       Date:  2016-01-13       Impact factor: 5.531

3.  The EANM practice guidelines for bone scintigraphy.

Authors:  T Van den Wyngaert; K Strobel; W U Kampen; T Kuwert; W van der Bruggen; H K Mohan; G Gnanasegaran; R Delgado-Bolton; W A Weber; M Beheshti; W Langsteger; F Giammarile; F M Mottaghy; F Paycha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-04       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.